25 Oesophageal Cancer

Oesophageal Cancer Brachytherapy

21

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 10/06/2019

15. REFERENCES

18. DE Carli DM, Araujo AF, Fagundes RB. Low prevalence of Barrett’s oesophagus in a risk area for oesophageal cancer in south of Brazil. Arq Ganstroenerol 2017; 54(4) : 305-7. 19. Dresen RC, Beets GL, Rutten HJ, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumour confined to the rectal wall? Radiology 2009; 252(1) : 71-80. 20. Dubecz A, Solymosi N, Stadlhuber RJ, et al. Does the incidence of adenocarcinoma of the oesophagus and gastric cardia continue to rise in the twenty-first century? A SEER database analysis. J Gastrointest Surg 2014; 18(1) : 124-29. 21. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53(7) : 925–930. 22. Francis SR, Orton A, Thorpe C, et al. Toxicity and outcomes in patients with and without oesophageal stents in locally advanced oesophageal cancer. Int J Radiat Oncol Biol Phys 2017; 99(4) : 884-894. 23. Fuccio L, Mandolesi D, Farioli A, Hassan C, Frazzoni L, Guido A, et al. Brachytherapy for the palliation of dysphagia owing to oesophageal cancer: A systematic review and meta-analysis of prospective studies. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2017; 122(3) : 332-9. 24. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the oesophagus (Radiation Therapy Oncology Group 25. Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, Clifton J: Defining the optimal treatment of locally advanced oesophageal cancer: a systematic review and decision analysis. Ann Thorac Surg 2007; 83 : 1257– 1264. 26. Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image-based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74(3) : 235-45. 27. Higuchi I, Yasuda T, Yano M et al. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced oesophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2008; 136(1) : 205-12. 28. Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the oesophagus (NCT02509286). BMC Cancer 2016; 12(7) : 681-92. 29. Homs MY, Steyerberg EW, Eikenboom WM, et al. Single-dose brachytherapy versus metals stent placement for the palliation of dysphagia from oesophageal cancer: multicenter randomized trial. Lancet 2004 364(9444) : 1497-1504. 30. ICRU Report 89: Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. Target concept. Journal of the ICRU 2013; Volume 13 (Issue 1-2) : 49-77. 31. Ishikawa H, Sakurai H, Yamakawa M, et al. Clinical outcomes and prognostic factors for patients with early oesophageal squamous cell carcinoma treated with definitive radiation therapy alone. J Clin Gastroenerol 2005 39(6) : 495-500. 32. Krug S and Michl P. Oesophageal cancer: New insights into a heterogeneous disease. Digestion 2017; 95(4) : 253-261. 33. Landau M, Hastings SM, Foxwell TJ, et al. Tumour budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial oesophageal adenocarcinoma. Mod Pathol 2014; 27(12) : 1578-1589. 34. Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 oesophageal adenocarcinoma: a retrospective review of esophagectomy specimens. Ann Surg Oncol 2011; 253 : 271-8. Study 9207): final report. Cancer 2000 88(5) : 988-95.

1. Abou Yehia Z, Mikhaeel GN, Smith G, et al. Does Bleomycin lung toxicity increase the risk of radiation pneumonitis in Hodgkin Lymphoma? Int J Radiat Oncol Biol Phys 2016; 96(5) : 951-958. 2. Al-Batran SE, HomannN, SchmalembergH, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecetabine (ECF/ECX) for resectable gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35 : suppl; abstr 4004. 3. Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of oesophageal cancer patients treated with radical intent. Can J Gastroenterol 2008; 22(4) : 393-8. 4. Amdal CD, Jacobsen AB, Sandstad B, et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol 2013 107(3) : 428-33. 5. Bacorro WR, Agas RAF, Cabrera SMR, et al. A novel applicator design for intracavitary brachytherapy of the nasopharynx: Simulated reconstruction, image-guided adaptive brachytherapy planning and dosimetry. Brachytherapy 2018; 17(4) : 709-17. 6. Barbour AP, Jones M, Brown I, et al. Risk stratification for early oesophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2010; 17 : 2494-2502. 7. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophagus: FFCD 9102. J Clin Oncol 2007; 25 : 1160 – 8. 8. Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the oesophagus and gastro-oesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005 18(3) : 131-9. 9. Brierly JD, Gospodarowicz MK, Wittekind C (Editors). TNM Classification of malignant tumours, 8th edition. 2016 ISBN: 978-1-119-26357-9. 10. Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for oesophageal cancer. Ann Surg 2017; 166(2) : 297-304. 11. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma 12. Buzurovic IM, Jorgen L, Hansen MS, et al. Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of oesophageal cancer. J Contemp Brachytherapy 2016; 8(4) : 319–25. 13. Calais G, Dorval E, Louisot P, et al. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III oesophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997; 38 : 769-75. 14. Choi J, Kim SG, Kim JS, et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable oesophageal cancer. Surg Endosc 2010; 24 : 1380-6. 15. Cook MB, Chow WH, Devesa SS, et al. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009; 101 : 855-859. 16. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced oesophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281(17) : 1623-7 17. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368(11) : 987-98. by EUS and histopathologic features. Gastrointest Endosc 2004; 60 : 703-710.